The Food and Drug Administration (FDA) has approved two separate vaccines to prevent respiratory syncytial virus (RSV) in older adults aged 60 and up.
GSK’s vaccine, Arexvy, was the first-ever RSV vaccine to be approved in the United States when it earned approval in early May. Pfizer’s RSV vaccine, called Abrysvo, followed suit just a month later.
Both vaccines show promising results in preventing severe RSV—a highly contagious virus that causes cold and flu-like symptoms. While RSV causes mild illness in most people, it can be deadly for young children and older adults, especially those with underlying medical conditions.